Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1-Reference-Cited by-同舟云学术

Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1

Published:2014-05-01 Issue:1 Volume:66 Page:65-73
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Herold Betsy C.,Dezzutti Charlene S.,Richardson Barbra A.,Marrazzo Jeanne,Mesquita Pedro M. M.,Carpenter Colleen,Huber Ashley,Louissaint Nicolette,Marzinke Mark A.,Hillier Sharon L.,Hendrix Craig W.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference33 articles.

1. . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.;Baeten;N Engl J Med,2012

2. . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.;Thigpen;N Engl J Med,2012

3. . Preexposure prophylaxis for HIV infection among African women.;Van Damme;N Engl J Med,2012

4. . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.;Abdool Karim;Science,2010

5. . Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid.;Venkataraman;J Immunol,2005

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States;Journal of the International AIDS Society;2024-03

2. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir;Frontiers in Cellular and Infection Microbiology;2023-04-19

3. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study;PLOS ONE;2022-10-10

4. The use of PSA as a biomarker of recent semen exposure in female reproductive health studies;Journal of Reproductive Immunology;2021-11

5. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial;PLOS Medicine;2021-02-03